Table 4.

Clinical adverse experiences

	Placebo N = 111 n (%)	Etoricoxib 90 mg qd N = 108 n (%)	Celecoxib 400 mg qd N = 107 n (%)	Ibuprofen 2,400 mg qd N = 107 n (%)
Clinical Adverse Experiences (AEs)
≥1 AE	40 (36.0)	50 (46.3)	45 (42.1)	45 (42.1)
≥1 Drug-related AE†	13 (11.7)	20 (18.5)	15 (14.0)	20 (18.7)
≥1 Serious AE	0 (0.0)	1 (0.9)	4 (3.7)	2 (1.9)
Discontinued due to an AE	8 (7.2)	12 (11.1)	11 (10.3)	11 (10.3)
Gastrointestinal (GI) Nuisance Symptoms‡
GI Symptom AEs	2 (1.8)	7 (6.5)	4 (3.7)	6 (5.6)
Discontinuations	0 (0.0)	2 (1.9)	0 (0.0)	2 (1.9)
Renovascular AEs
Lower Extremity Edema	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Discontinuations	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Congestive Heart Failure	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypertension§	1 (0.9)	4 (3.7)	1 (0.9)	4 (3.7)
Discontinuations	0 (0.0)	2 (1.9)	0 (0.0)	0 (0.0)

^†Determined by the investigator to be possibly, probably or definitely drug related.

^‡Includes abdominal pain, abdominal discomfort, acid reflux, dyspepsia, epigastric discomfort, heartburn, nausea and vomiting.

^§Hypertension was diagnosed by individual investigators; a formal set of parameters was not provided.